| DRNA Market Cap History Table | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Below is a table of the DRNA market cap history going back to 1/30/2014:
Also see: DRNA Shares Outstanding History and DRNA YTD Return |
DRNA Market Cap History — Dicerna Pharmaceuticals Capitalization Over Time
As of 11/4/2021 Dicerna Pharmaceuticals has a market cap of 1.74 billion. Investors often follow the DRNA market cap history to compare the size of the company over time.
This page shows DRNA market capitalization trends over time, with 35 market cap datapoints presented, dating back to 1/30/2014.
| DRNA Market Cap History Chart | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
DRNA Historical Market Cap: +12.03% CAGR 
Mouse over chart for data details
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| DRNA Stock Price Chart |
| About Dicerna Pharmaceuticals Inc |
| Dicerna Pharmaceuticals is a biopharmaceutical company focused on discovering, developing, and commercializing medicines that are designed to utilize ribonucleic acid interference to silence selectively genes that cause or contribute to disease. Nedosiran is Co.'s investigational product candidate for the treatment of primary hyperoxaluria (PH) type 1, PH type 2, and PH type 3. Co.'s GalXC product candidate, RG6346, is for the treatment of chronic hepatitis B virus (HBV) infection. Therapies for HBV include nucleoside analogs and pegylated interferon regimens. Co.'s another GalXC product candidate, belcesiran, is for the treatment of alpha-1 antitrypsin deficiency-associated liver disease. We show 35 historical shares outstanding datapoints in our DRNA shares outstanding history coverage, used to compute DRNA market cap on those dates. Understanding the changing numbers of shares outstanding, the changing share price, and the resulting changing DRNA market cap history over the course of time is important for investors interested in comparing DRNA's market cap history versus its peers. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies, and then calculating their respective market caps. Comparing the share price of DRNA versus a peer is one thing; comparing DRNA market cap versus a peer is a completely different story. Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares), the market cap for a company like DRNA can fluctuate over the course of history. With this page we aim to empower investors researching DRNA by allowing them to research the DRNA market cap history. |
| DRNA Current Stock Quote |
Quotes delayed 20 minutes  Free DRNA Email Alerts:
Get Dividend Alerts 
Get SEC Filing Alerts
|
| Video: The Importance of Market Cap | |
|
Video: The Importance of Market Cap
| DRNA Share Performance |
| Market Cap Peers |
| Dicerna Pharmaceuticals (DRNA) is categorized under the Healthcare sector; to help you further research historical market cap numbers, below are some other companies in the same sector:
DRRX Market Cap History DSGN Market Cap History DTIL Market Cap History DVA Market Cap History DVAX Market Cap History DVCR Market Cap History DWTX Market Cap History DXCM Market Cap History DYAI Market Cap History DYN Market Cap History More Healthcare companies » |
DRNA Market Cap History | www.MarketCapHistory.com | Copyright © 2017 - 2026, All Rights Reserved
Nothing in MarketCapHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you
agree to the following Full Disclaimer & Terms of Use and
Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at
least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.
